JPMorgan Chase & Co. trimmed its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 69.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,114 shares of the company's stock after selling 46,948 shares during the quarter. JPMorgan Chase & Co. owned about 0.09% of UroGen Pharma worth $225,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Rhumbline Advisers increased its stake in UroGen Pharma by 2.8% during the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company's stock worth $546,000 after purchasing an additional 1,402 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in UroGen Pharma by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock worth $996,000 after acquiring an additional 3,024 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of UroGen Pharma in the 4th quarter valued at $59,000. Tidal Investments LLC increased its holdings in UroGen Pharma by 19.1% in the third quarter. Tidal Investments LLC now owns 37,595 shares of the company's stock valued at $477,000 after buying an additional 6,030 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in UroGen Pharma by 44.1% during the 4th quarter. SG Americas Securities LLC now owns 20,269 shares of the company's stock worth $216,000 after buying an additional 6,207 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.
UroGen Pharma Price Performance
Shares of URGN stock traded down $1.26 during mid-day trading on Tuesday, reaching $9.69. The stock had a trading volume of 802,871 shares, compared to its average volume of 537,249. The company has a market cap of $446.78 million, a P/E ratio of -3.08 and a beta of 0.66. UroGen Pharma Ltd. has a 12-month low of $8.94 and a 12-month high of $20.70. The business has a 50-day simple moving average of $10.57 and a 200 day simple moving average of $11.03. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. On average, sell-side analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on the stock. The Goldman Sachs Group dropped their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Monday, April 28th. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target for the company. Guggenheim reissued a "buy" rating on shares of UroGen Pharma in a report on Tuesday, April 29th. Finally, Scotiabank started coverage on UroGen Pharma in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price target for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $32.86.
Read Our Latest Analysis on UroGen Pharma
UroGen Pharma Company Profile
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Read More
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
